Definium Therapeutics

American clinical-stage biopharmaceutical company developing psychedelic-based treatments

MNMD Nasdaq · home listing MMQ Frankfurt SE MMED Cboe Canada ISIN CA60255C8850 SEC CIK 1813814
Follow Definium Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$51M +24.2% vs same quarter last year
EPS, diluted −$0.46 +41% vs same quarter last year
Operating cash flow −$53M −79.2% vs same quarter last year
Operating income −$72.3M −58.3% vs same quarter last year
Net income by quarter
−$34.7M
−$23.3M
−$42.7M
−$67.3M
−$50.4M
−$77.1M
−$159M
−$51M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$200M−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$183.8M
FY24−$108.7M
FY23−$95.7M
FY22−$56.8M
FY21−$93M
FY20−$33.9M
FY19-